Under this exclusive agreement, Arecor will use its proprietary technology platform Arestat™ to develop a stable and novel liquid formulation of a proprietary product in a ready-to-administer (RTA) infusion bag. RTA medicines have the potential to significantly enhance patient care whilst reducing associated healthcare costs by providing safe, stable and easy to use products for healthcare professionals
Arestat™ is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides. Arestat™ has the unique potential to deliver superior reformulations of existing product which would otherwise not be possible.
Sarah Howell, Chief Executive Officer of Arecor, said: "This is the second RTA collaboration that we have announced in recent weeks involving our proprietary technology platform Arestat™. It is a further project for an existing pharmaceutical partner which demonstrates the value of our technology and expertise together with the strength of our commercial relationships”.
Arecor signs a new feasibility study agreement with top five pharma company
14 February 2020
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical partner will fund the feasibility study and has an exclusive option to a global royalty bearing licence to the new formulation and Arecor’s associated Intellectual Property.